Glenmede Trust CO Na Tcr2 Therapeutics Inc. Transaction History

Glenmede Trust CO Na

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $135,841 - $295,343	-16,095 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $11,667 - $17,568	-711 Reduced 4.23%	16,095 $264,000
Q1 2021 May 18, 2021	BUY	$20.38 - $34.07 $5,217 - $8,721	256 Added 1.55%	16,806 $371,000
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $314,450 - $540,026	16,550 New	16,550 $511,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.